vs

Side-by-side financial comparison of Charles River Laboratories (CRL) and RB GLOBAL INC. (RBA). Click either name above to swap in a different company.

RB GLOBAL INC. is the larger business by last-quarter revenue ($1.2B vs $994.2M, roughly 1.2× Charles River Laboratories). RB GLOBAL INC. runs the higher net margin — 9.1% vs -27.8%, a 36.9% gap on every dollar of revenue. On growth, RB GLOBAL INC. posted the faster year-over-year revenue change (5.4% vs -0.8%). RB GLOBAL INC. produced more free cash flow last quarter ($186.5M vs $58.6M). Over the past eight quarters, RB GLOBAL INC.'s revenue compounded faster (6.3% CAGR vs -0.9%).

Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices.

Ritchie Bros. Auctioneers (RBA), or simply Ritchie Bros., is a publicly traded company legally domiciled in Canada with headquarters in Westchester, Illinois. Its common shares are traded on the Toronto Stock Exchange and the New York Stock Exchange.

CRL vs RBA — Head-to-Head

Bigger by revenue
RBA
RBA
1.2× larger
RBA
$1.2B
$994.2M
CRL
Growing faster (revenue YoY)
RBA
RBA
+6.2% gap
RBA
5.4%
-0.8%
CRL
Higher net margin
RBA
RBA
36.9% more per $
RBA
9.1%
-27.8%
CRL
More free cash flow
RBA
RBA
$127.9M more FCF
RBA
$186.5M
$58.6M
CRL
Faster 2-yr revenue CAGR
RBA
RBA
Annualised
RBA
6.3%
-0.9%
CRL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CRL
CRL
RBA
RBA
Revenue
$994.2M
$1.2B
Net Profit
$-276.6M
$109.7M
Gross Margin
Operating Margin
-28.5%
14.7%
Net Margin
-27.8%
9.1%
Revenue YoY
-0.8%
5.4%
Net Profit YoY
-28.9%
-7.4%
EPS (diluted)
$-5.57
$0.53

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CRL
CRL
RBA
RBA
Q4 25
$994.2M
$1.2B
Q3 25
$1.0B
$1.1B
Q2 25
$1.0B
$1.2B
Q1 25
$984.2M
$1.1B
Q4 24
$1.0B
$1.1B
Q3 24
$1.0B
$981.8M
Q2 24
$1.0B
$1.1B
Q1 24
$1.0B
$1.1B
Net Profit
CRL
CRL
RBA
RBA
Q4 25
$-276.6M
$109.7M
Q3 25
$54.4M
$95.5M
Q2 25
$52.3M
$109.8M
Q1 25
$25.5M
$113.4M
Q4 24
$-214.5M
$118.5M
Q3 24
$69.7M
$76.1M
Q2 24
$94.1M
$111.1M
Q1 24
$73.0M
$107.4M
Gross Margin
CRL
CRL
RBA
RBA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
34.6%
Q2 24
34.5%
Q1 24
34.1%
Operating Margin
CRL
CRL
RBA
RBA
Q4 25
-28.5%
14.7%
Q3 25
13.3%
14.5%
Q2 25
9.7%
15.9%
Q1 25
7.6%
17.1%
Q4 24
-16.7%
18.1%
Q3 24
11.6%
15.6%
Q2 24
14.8%
18.4%
Q1 24
12.5%
18.7%
Net Margin
CRL
CRL
RBA
RBA
Q4 25
-27.8%
9.1%
Q3 25
5.4%
8.7%
Q2 25
5.1%
9.3%
Q1 25
2.6%
10.2%
Q4 24
-21.4%
10.4%
Q3 24
6.9%
7.8%
Q2 24
9.2%
10.1%
Q1 24
7.2%
10.1%
EPS (diluted)
CRL
CRL
RBA
RBA
Q4 25
$-5.57
$0.53
Q3 25
$1.10
$0.43
Q2 25
$1.06
$0.53
Q1 25
$0.50
$0.55
Q4 24
$-4.17
$0.58
Q3 24
$1.33
$0.36
Q2 24
$1.74
$0.54
Q1 24
$1.30
$0.53

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CRL
CRL
RBA
RBA
Cash + ST InvestmentsLiquidity on hand
$213.8M
$531.5M
Total DebtLower is stronger
$2.1B
$2.3B
Stockholders' EquityBook value
$3.2B
$5.6B
Total Assets
$7.1B
$12.1B
Debt / EquityLower = less leverage
0.68×
0.42×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CRL
CRL
RBA
RBA
Q4 25
$213.8M
$531.5M
Q3 25
$207.1M
$674.7M
Q2 25
$182.8M
$710.2M
Q1 25
$229.4M
$578.1M
Q4 24
$194.6M
$533.9M
Q3 24
$210.2M
$650.7M
Q2 24
$179.2M
$599.5M
Q1 24
$327.0M
$462.8M
Total Debt
CRL
CRL
RBA
RBA
Q4 25
$2.1B
$2.3B
Q3 25
$2.2B
$2.6B
Q2 25
$2.3B
$2.6B
Q1 25
$2.5B
$2.6B
Q4 24
$2.2B
$2.6B
Q3 24
$2.3B
$2.7B
Q2 24
$2.4B
$2.8B
Q1 24
$2.7B
$2.9B
Stockholders' Equity
CRL
CRL
RBA
RBA
Q4 25
$3.2B
$5.6B
Q3 25
$3.4B
$5.5B
Q2 25
$3.4B
$5.5B
Q1 25
$3.2B
$5.3B
Q4 24
$3.5B
$5.2B
Q3 24
$3.8B
$5.2B
Q2 24
$3.7B
$5.2B
Q1 24
$3.6B
$5.1B
Total Assets
CRL
CRL
RBA
RBA
Q4 25
$7.1B
$12.1B
Q3 25
$7.5B
$12.2B
Q2 25
$7.6B
$12.2B
Q1 25
$7.6B
$11.9B
Q4 24
$7.5B
$11.8B
Q3 24
$8.0B
$11.9B
Q2 24
$7.9B
$12.1B
Q1 24
$8.2B
$12.0B
Debt / Equity
CRL
CRL
RBA
RBA
Q4 25
0.68×
0.42×
Q3 25
0.64×
0.47×
Q2 25
0.70×
0.47×
Q1 25
0.79×
0.50×
Q4 24
0.65×
0.50×
Q3 24
0.62×
0.52×
Q2 24
0.65×
0.55×
Q1 24
0.73×
0.58×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CRL
CRL
RBA
RBA
Operating Cash FlowLast quarter
$147.5M
$255.2M
Free Cash FlowOCF − Capex
$58.6M
$186.5M
FCF MarginFCF / Revenue
5.9%
15.5%
Capex IntensityCapex / Revenue
8.9%
5.7%
Cash ConversionOCF / Net Profit
2.33×
TTM Free Cash FlowTrailing 4 quarters
$518.5M
$719.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CRL
CRL
RBA
RBA
Q4 25
$147.5M
$255.2M
Q3 25
$213.8M
$239.7M
Q2 25
$204.6M
$326.5M
Q1 25
$171.7M
$156.8M
Q4 24
$159.4M
$184.5M
Q3 24
$251.8M
$285.4M
Q2 24
$193.5M
$337.3M
Q1 24
$129.9M
$124.8M
Free Cash Flow
CRL
CRL
RBA
RBA
Q4 25
$58.6M
$186.5M
Q3 25
$178.2M
$188.5M
Q2 25
$169.3M
$241.7M
Q1 25
$112.4M
$102.5M
Q4 24
$83.7M
$127.9M
Q3 24
$213.1M
$248.5M
Q2 24
$154.0M
$308.6M
Q1 24
$50.7M
$79.6M
FCF Margin
CRL
CRL
RBA
RBA
Q4 25
5.9%
15.5%
Q3 25
17.7%
17.3%
Q2 25
16.4%
20.4%
Q1 25
11.4%
9.2%
Q4 24
8.4%
11.2%
Q3 24
21.1%
25.3%
Q2 24
15.0%
28.2%
Q1 24
5.0%
7.5%
Capex Intensity
CRL
CRL
RBA
RBA
Q4 25
8.9%
5.7%
Q3 25
3.5%
4.7%
Q2 25
3.4%
7.2%
Q1 25
6.0%
4.9%
Q4 24
7.5%
5.0%
Q3 24
3.8%
3.8%
Q2 24
3.8%
2.6%
Q1 24
7.8%
4.2%
Cash Conversion
CRL
CRL
RBA
RBA
Q4 25
2.33×
Q3 25
3.93×
2.51×
Q2 25
3.91×
2.97×
Q1 25
6.74×
1.38×
Q4 24
1.56×
Q3 24
3.61×
3.75×
Q2 24
2.06×
3.04×
Q1 24
1.78×
1.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CRL
CRL

Discovery And Safety Assessment Segment$591.6M60%
Manufacturing Support Segment$196.4M20%
Transferred At Point In Time$108.0M11%
Transferred Over Time$98.3M10%

RBA
RBA

Buyer Revenue$577.2M48%
Seller Revenue$255.2M21%
CA$199.0M17%
Other$124.7M10%
AU$47.3M4%

Related Comparisons